Allosteric modulation of heterodimeric G-protein-coupled receptors

Trends in Pharmacological Sciences

Volumn 28, Issue 12, 2007, Pages 615-620

  Milligan, Graeme ^a   Smith, Nicola J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM SENSING RECEPTOR; CANNABINOID 1 RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; DOPAMINE; G PROTEIN COUPLED RECEPTOR; HETERODIMER; KAPPA OPIATE RECEPTOR; MARAVIROC; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MU OPIATE RECEPTOR; OREXIN 1 RECEPTOR; RIMONABANT;

ALLOSTERISM; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; BODY MASS; DIMERIZATION; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LIGAND BINDING; NONHUMAN; OBESITY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING;

ALLOSTERIC REGULATION; ANIMALS; DIMERIZATION; HUMANS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CCR2; RECEPTORS, CCR5; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE;

EID: 36448968578     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.11.001     Document Type: Article

References (39)

1. Hopkins A.L., and Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 1 (2002) 727-730
2. Jacoby E., et al. The 7 TM G-protein-coupled receptor target family. ChemMedChem 1 (2006) 761-782
3. Fredriksson R., and Schiöth H.B. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Mol. Pharmacol. 67 (2005) 1414-1425
4. Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol. Ther. 109 (2006) 339-365
5. Brauner-Osborne H., et al. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr. Drug Targets 8 (2007) 169-184
6. Biswas P., et al. Access denied? The status of co-receptor inhibition to counter HIV entry. Expert Opin. Pharmacother. 8 (2007) 923-933
7. Dorr P., et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49 (2005) 4721-4732
8. Gao Z.G., and Jacobson K.A. Keynote review: allosterism in membrane receptors. Drug Discov. Today 11 (2006) 191-202
9. Langmead C.J., and Christopoulos A. Allosteric agonists of 7TM receptors: expanding the pharmacological toolbox. Trends Pharmacol. Sci. 27 (2006) 475-481
10. Ballesteros J., and Ransom J. In-Target versus Off-Target allosteric modulators of GPCRs. Drug Discov. Today: Therapeutic Strategies 3 (2006) 445-450
11. Marianayagam N.J., et al. The power of two: protein dimerization in biology. Trends Biochem. Sci. 29 (2004) 618-625
12. Milligan G. G protein-coupled receptor dimerisation: molecular basis and relevance to function. Biochim. Biophys. Acta 1768 (2007) 825-835
13. Milligan G. GPCR hetero-dimers: pharmacology, function and relevance to drug discovery. Drug Discov. Today 11 (2006) 541-549
14. Franco R., et al. Dimer-based model for heptaspanning membrane receptors. Trends Biochem. Sci. 30 (2005) 360-366
15. Franco R., et al. The two-state dimer receptor model: a general model for receptor dimers. Mol. Pharmacol. 69 (2006) 1905-1912
16. 2-adrenoceptor. Cell. Signal. 19 (2007) 1928-1938
17. Hilairet S., et al. Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. J. Biol. Chem. 278 (2003) 23731-23737
18. Ellis J., et al. Orexin-1 receptor-cannabinoid CB1 receptor hetero-dimerization results in both ligand-dependent and -independent co-ordinated alterations of receptor localization and function. J. Biol. Chem. 281 (2006) 38812-38824
19. El-Asmar L., et al. Evidence for negative binding cooperativity within CCR5-CCR2b heterodimers. Mol. Pharmacol. 67 (2005) 460-469
20. Springael J.Y., et al. Allosteric modulation of binding properties between units of chemokine receptor homo- and hetero-oligomers. Mol. Pharmacol. 69 (2006) 1652-1666
21. George S.R., et al. Oligomerization of mu and delta-opioid receptors. Generation of novel functional properties. J. Biol. Chem. 275 (2000) 26128-26135
22. Vohra S., et al. Computational studies of family A and family B GPCRs. Biochem. Soc. Trans. 35 (2007) 749-754
23. Waldhoer M., et al. A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 9050-9055
24. Kostenis E., et al. Techniques: promiscuous Galpha proteins in basic research and drug discovery. Trends Pharmacol. Sci. 26 (2005) 595-602
25. Rashid A.J., et al. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 654-659
26. Kearn C.S., et al. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?. Mol. Pharmacol. 67 (2005) 1697-1704
27. Milligan G., and Kostenis E. Hetero-trimeric G proteins: a short history. Br. J. Pharmacol. 147 S1 (2006) S46-S55
28. Damian M., et al. Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J. 25 (2006) 5693-5702
29. Xu H., et al. Different functional roles of T1R subunits in the heteromeric taste receptors. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 14258-14263
30. Pin J.P., et al. International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol. Rev. 59 (2007) 5-13
31. Binet V., et al. The heptahelical domain of GABA(B2) is activated directly by CGP7930, a positive allosteric modulator of the GABA(B) receptor. J. Biol. Chem. 279 (2004) 29085-29091
32. Padwal R.S., and Mujumdar S.R. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369 (2007) 71-77
33. Bouaboula M., et al. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272 (1997) 22330-22339
34. Schlyer S., and Horuk R. I want a new drug: G-protein-coupled receptors in drug development. Drug Discov. Today 11 (2006) 481-493
35. Horuk R. Chemokines. ScientificWorldJournal 19 (2007) 224-232
36. Levoye A., et al. The orphan GPR50 receptor specifically inhibits MT1 melatonin receptor function through heterodimerization. EMBO J. 25 (2006) 3012-3023
37. Kostenis E., et al. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 111 (2005) 1806-1813
38. McLaughlin J.N., et al. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 5662-5667
39. Ciruela F., et al. Presynaptic control of striatal glutamateric neurotranmission by adenosine A1-A2a receptor heteromers. J. Neurosci. 26 (2006) 2080-2087